OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005

Mahdi Saghari, Pim Gal, Sally Gilbert, Martin Yateman, Ben Porter-Brown, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Hendrika W Grievink, Erica S Klaassen, Kirsten R Bergmann, Jacobus Burggraaf, Martijn B A van Doorn, John Powell, Matthijs Moerland, Robert Rissmann, Mahdi Saghari, Pim Gal, Sally Gilbert, Martin Yateman, Ben Porter-Brown, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Hendrika W Grievink, Erica S Klaassen, Kirsten R Bergmann, Jacobus Burggraaf, Martijn B A van Doorn, John Powell, Matthijs Moerland, Robert Rissmann

Abstract

The safety, tolerability, immunogenicity, and pharmacokinetic (PK) profile of an anti-OX40L monoclonal antibody (KY1005, currently amlitelimab) were evaluated. Pharmacodynamic (PD) effects were explored using keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT) immunizations. Sixty-four healthy male subjects (26.5 ± 6.0 years) were randomized to single doses of 0.006, 0.018, or 0.05 mg/kg, or multiple doses of 0.15, 0.45, 1.35, 4, or 12 mg/kg KY1005, or placebo (6:2). Serum KY1005 concentrations were measured. Antibody responses upon KLH and TT immunizations and skin response upon intradermal KLH administration were performed. PD data were analyzed using repeated measures analysis of covariances (ANCOVAs) and post hoc exposure-response modeling. No serious adverse events occurred and all adverse events were temporary and of mild or moderate severity. A nonlinear increase in mean serum KY1005 concentrations was observed (median time to maximum concentration (Tmax ) ~ 4 hours, geometric mean terminal half-life (t½) ~ 24 days). Cutaneous blood perfusion (estimated difference (ED) -13.4 arbitrary unit (AU), 95% confidence interval (CI) -23.0 AU to -3.8 AU) and erythema quantified as average redness (ED -0.23 AU, 95% CI -0.35 AU to -0.11 AU) decreased after KY1005 treatment at doses of 0.45 mg/kg and above. Exposure-response analysis displayed a statistically significant treatment effect on anti-KLH antibody titers (IgG maximum effect (Emax ) -0.58 AU, 95% CI -1.10 AU to -0.06 AU) and skin response (erythema Emax -0.20 AU, 95% CI -0.29 AU to -0.11 AU). Administration of KY1005 demonstrated an acceptable safety and tolerability profile and PK analyses displayed a nonlinear profile of KY1005. Despite the observed variability, skin challenge response after KY1005 treatment indicated pharmacological activity of KY1005. Therefore, KY1005 shows potential as a novel pharmacological treatment in immune-mediated disorders.

Trial registration: ClinicalTrials.gov NCT03161288.

Conflict of interest statement

J.P., S.G., M.Y., B.P.B., N.B., S.Q., and R.W. are employed by the sponsor. All other authors declared no competing interests for this work.

© 2022 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Figures

Figure 1
Figure 1
Illustrations of LSCI basal flow and erythema assessed as average redness with multispectral imaging. Images were taken at intradermal KLH injection site 2 days after intradermal KLH administration of a subject treated with an initial KY1005 12 mg/kg dose (left images) and a subject that received placebo (right images). KLH, keyhole limpet hemocyanin; LSCI, laser speckle contrast imaging.
Figure 2
Figure 2
KY1005 serum concentrations (μg/mL). Data displayed on log10 scale as mean (SD).
Figure 3
Figure 3
Anti‐KLH IgM (a) and IgG antibody titers (b), anti‐TT IgM (c), and IgG antibody titers (d) 21 days after KLH and TT immunizations, cutaneous blood perfusion by LSCI basal flow (e) and LSCI flare (f), erythema by multispectral imaging average redness (g), and multispectral imaging CIELab a* (h) 2 days after intradermal KLH administration by treatment group. Data are shown as estimated difference percentage change (95% confidence interval) for a to d and as mean CFB (SD) for e to h. AU, arbitrary unit; CFB, change from baseline; ED, estimated difference; i.d., intradermal; KLH, keyhole limpet hemocyanin; LSCI, laser speckle contrast imaging; TT, tetanus toxoid. The P values are based on estimated differences between groups with correction for baseline measurements and saline administration. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4
Figure 4
Emax model of KY1005 exposure and anti‐KLH IgM (a), anti‐KLH IgG (b), anti‐TT IgM (c), anti‐TT IgG (d), LSCI basal flow (e), LSCI flare (f), multispectral imaging average redness (g), and multispectral imaging CIELab a* (h). Dots represent individual data points. Black squares (error bars) represent mean (SD) of observed data per dose level. Black line (grey area) represents model predicted mean (90% confidence interval). Data are shown as log10 change from baseline ratios vs. KY1005 concentration. CFB, change from baseline; Emax, maximum effect; KLH, keyhole limpet hemocyanin; LSCI, laser speckle contrast imaging; TT, tetanus toxoid.

References

    1. Munks, M.W. , Mourich, D.V. , Mittler, R.S. , Weinberg, A.D. & Hill, A.B. 4–1BB and OX40 stimulation enhance CD8 and CD4 T‐cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112, 559–566 (2004).
    1. Zaini, J. et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Investig. 117, 3330–3338 (2007).
    1. Melero, I. , Hirschhorn‐Cymerman, D. , Morales‐Kastresana, A. , Sanmamed, M.F. & Wolchok, J.D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19, 1044–1053 (2013).
    1. Baumann, R. , Yousefi, S. , Simon, D. , Russmann, S. , Mueller, C. & Simon, H.‐U. Functional expression of CD134 by neutrophils. Eur. J. Immunol. 34, 2268–2275 (2004).
    1. Gramaglia, I. , Jember, A. , Pippig, S.D. , Weinberg, A.D. , Killeen, N. & Croft, M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165, 3043–3050 (2000).
    1. Maxwell, J.R. , Weinberg, A. , Prell, R.A. & Vella, A.T. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164, 107–112 (2000).
    1. Mestas, J. , Crampton, S.P. , Hori, T. & Hughes, C.C.W. Endothelial cell co‐stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. Int. Immunol. 17, 737–747 (2005).
    1. Linton, P.‐J. et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197, 875–883 (2003).
    1. Jenkins, S.J. , Perona‐Wright, G. , Worsley, A.G.F. , Ishii, N. & MacDonald, A.S. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. J. Immunol. 179, 3515–3523 (2007).
    1. Karulf, M. , Kelly, A. , Weinberg, A.D. & Gold, J.A. OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J. Immunol. 185, 4856–4862 (2010).
    1. Imura, A. et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183, 2185–2195 (1996).
    1. Krimmer, D.I. et al. CD40 and OX40 ligand are differentially regulated on asthmatic airway smooth muscle. Allergy 64, 1074–1082 (2009).
    1. Nakae, S. et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176, 2238–2248 (2006).
    1. Kashiwakura, J.‐I. , Yokoi, H. , Saito, H. & Okayama, Y. T Cell proliferation by direct cross‐talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung‐cultured mast cells. J. Immunol. 173, 5247–5257 (2004).
    1. Takeda, I. et al. Distinct roles for the OX40‐OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172, 3580–3589 (2004).
    1. Webb, G.J. , Hirschfield, G.M. & Lane, P.J.L. OX40, OX40L and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 50, 312–332 (2016).
    1. Gaspal, F.M. et al. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3‐deficient mice. J. Exp. Med. 208, 1579–1584 (2011).
    1. Gwyer Findlay, E. et al. OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc. Natl. Acad. Sci. USA 111, 2289–2294 (2014).
    1. Murata, K. , Nose, M. , Ndhlovu, L.C. , Sato, T. , Sugamura, K. & Ishii, N. Constitutive OX40/OX40 ligand interaction induces autoimmune‐like diseases. J. Immunol. 169, 4628–4636 (2002).
    1. Guttman‐Yassky, E. et al. GBR 830, an anti‐OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 144, 482–493 (2019).
    1. Papp, K.A. , Gooderham, M.J. , Girard, G. , Raman, M. & Strout, V. Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1324–1332 (2017).
    1. Pakala, S.V. , Bansal‐Pakala, P. , Halteman, B.S. & Croft, M. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur. J. Immunol. 34, 3039–3046 (2004).
    1. Totsuka, T. et al. Therapeutic effect of anti‐OX40L and anti‐TNF‐α MAbs in a murine model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G595–G603 (2003).
    1. Yoshioka, T. et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30, 2815–2823 (2000).
    1. Zhang, Z. et al. Activation of OX40 augments Th17 cytokine expression and antigen‐specific uveitis. Am. J. Pathol. 177, 2912–2920 (2010).
    1. Nohara, C. et al. Amelioration of experimental autoimmune encephalomyelitis with anti‐OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J. Immunol. 166, 2108–2115 (2001).
    1. Elyaman, W. et al. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am. J. Pathol. 173, 411–422 (2008).
    1. Gauvreau, G.M. et al. OX 40L blockade and allergen‐induced airway responses in subjects with mild asthma. Clin. Exp. Allergy 44, 29–37 (2014).
    1. Tkachev, V. et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reg reconstitution after transplant. Sci. Transl. Med. 9, eaan3085 (2017).
    1. Saghari, M. et al. A randomized controlled trial with a delayed‐type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man. Br. J. Clin. Pharmacol. 87, 1953–1962 (2021).
    1. Boulton, C. , Meiser, K. , David, O.J. & Schmouder, R. Pharmacodynamic effects of steady‐state fingolimod on antibody response in healthy volunteers: a 4‐week, randomized, placebo‐controlled, parallel‐group, multiple‐dose study. J. Clin. Pharmacol. 52, 1879–1890 (2012).
    1. Ferbas, J. et al. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus. Br. J. Clin. Pharmacol. 76, 188–202 (2013).
    1. Smith, A. , Vollmer‐Conna, U. , Bennett, B. , Wakefield, D. , Hickie, I. & Lloyd, A. The relationship between distress and the development of a primary immune response to a novel antigen. Brain Behav. Immun. 18, 65–75 (2004).
    1. Smith, A.J. , Vollmer‐Conna, U. , Bennett, B. , Hickie, I.B. & Lloyd, A.R. Influences of distress and alcohol consumption on the development of a delayed‐type hypersensitivity skin test response. Psychosom. Med. 66, 614–619 (2004).
    1. Smith, T.P. , Kennedy, S.L. & Fleshner, M. Influence of age and physical activity on the primary in vivo antibody and T cell‐mediated responses in men. J. Appl. Physiol. 97, 491–498 (2004).
    1. Boelens, P.G. et al. Primary immune response to keyhole limpet haemocyanin following trauma in relation to low plasma glutamine. Clin. Exp. Immunol. 136, 356–364 (2004).
    1. Ly, B.C.K. , Dyer, E.B. , Feig, J.L. , Chien, A.L. & Del Bino, S. Research techniques made simple: cutaneous colorimetry: a reliable technique for objective skin color measurement. J. Invest. Dermatol. 140, 3–12 (2020).
    1. Giezen, T.J. , Mantel‐Teeuwisse, A.K. , Straus Sabine, M.J.M. , Schellekens, H. , Leufkens, H.G.M. & Egberts, A.C.G. Safety‐related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300, 1887 (2008).
    1. Mager, D.E. Target‐mediated drug disposition and dynamics. Biochem. Pharmacol. 72, 1–10 (2006).
    1. Liu, L. Pharmacokinetics of monoclonal antibodies and Fc‐fusion proteins. Protein Cell 9, 15–32 (2018).
    1. Stüber, E. & Strober, W. The T cell‐B cell interaction via OX40‐OX40L is necessary for the T cell‐dependent humoral immune response. J. Exp. Med. 183, 979–989 (1996).
    1. Kurosaki, T. , Kometani, K. & Ise, W. Memory B cells. Nat. Rev. Immunol. 15, 149–159 (2015).
    1. Blum, J.S. , Wearsch, P.A. & Cresswell, P. Pathways of antigen processing. Annu. Rev. Immunol. 31, 443–473 (2013).
    1. Crotty, S. A brief history of T cell help to B cells. Nat. Rev. Immunol. 15, 185–189 (2015).
    1. Swaminathan, A. , Lucas, R.M. , Dear, K. & McMichael, A.J. Keyhole limpet haemocyanin ‐ a model antigen for human immunotoxicological studies. Br. J. Clin. Pharmacol. 78, 1135–1142 (2014).

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever